Translatability of preclinical to early clinical tolerable and pharmacologically active dose ranges for central nervous system active drugs

Guilherme S Ferreira, Francis M Dijkstra*, Désirée H Veening-Griffioen, Wouter P C Boon, Huub Schellekens, Ellen H M Moors, Peter J K van Meer, Frederik E Stuurman, Joop M A van Gerven

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

The primary purpose of this study was to assess the translatability of preclinical to early clinical tolerable and pharmacologically active dose ranges for central nervous system (CNS) active drugs. As a part of this, IBs were reviewed on reporting quality. Investigator's Brochures (IBs) of studies performed at the Centre for Human Drug Research (CHDR) reporting statistically significant results of CNS activity related to the drug's mechanism of action were included. The quality of IBs was assessed based on the presence of a rationale for the chosen animal model, completeness of pharmacokinetic (PK) results in reporting and internal validity information of the preclinical evidence. The IB-derisk tool was used to generate preclinical and early clinical data overviews data. For each compound, the overlap between pharmacologically active dose ranges and well-tolerated levels was calculated for three pharmacokinetic (PK) parameters: human equivalent dose (HED), maximum plasma concentration (C max) and area under the curve (AUC). Twenty-five IBs were included. In general, the quality of reporting in IBs was assessed as poor. About a third of studies did not explore the entire concentration-effect curve (pre)clinically. Single dose tolerability ranges were most accurately predicted by C max. Human equivalent dose and AUC were the best predictors of pharmacologically active ranges. Tolerable and pharmacologically active dose ranges in healthy volunteers can be reasonably well predicted from preclinical data with the IB-derisk tool. The translatability of preclinical studies can be improved by applying a higher reporting standard in IBs including comparable PK measurements across all preclinical and clinical studies.

Original languageEnglish
Article number74
Number of pages12
JournalTranslational Psychiatry
Volume13
Issue number1
DOIs
Publication statusPublished - Dec 2023

Keywords

  • Animals
  • Humans
  • Irritable Bowel Syndrome
  • Area Under Curve
  • Health Status
  • Healthy Volunteers
  • Central Nervous System

Fingerprint

Dive into the research topics of 'Translatability of preclinical to early clinical tolerable and pharmacologically active dose ranges for central nervous system active drugs'. Together they form a unique fingerprint.

Cite this